Detalles de la búsqueda
1.
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Ann Hematol
; 97(9): 1745, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29934835
2.
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Ann Hematol
; 97(10): 1825-1839, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29862437
3.
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Int J Mol Sci
; 18(2)2017 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28212292
4.
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Blood
; 129(3): 383-385, 2017 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27879257
5.
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Ann Hematol
; 93(11): 1825-38, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24951123
6.
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Ann Hematol
; 90(9): 1083-91, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21350830
7.
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Cancer Med
; 8(4): 1401-1405, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30888118
8.
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Wien Klin Wochenschr
; 130(3-4): 115-125, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29383443
9.
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
J Hematol Oncol
; 9: 39, 2016 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-27084507
10.
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Haematologica
; 89(5): 528-40, 2004 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15136215
11.
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
Hematol J
; 5(5): 410-8, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15448667
12.
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Cytometry B Clin Cytom
; 62(1): 25-38, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15468339
13.
A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13).
Mol Cytogenet
; 6(1): 40, 2013 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-24079663
14.
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
J Hematol Oncol
; 6: 32, 2013 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-23627920
15.
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Blood
; 104(10): 3078-85, 2004 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15284114
Resultados
1 -
15
de 15
1
Próxima >
>>